¾ËÃ÷ÇÏÀ̸Ӻ´¿¡¼ ÀÓ»ó¾à¹°½ÃÇèÀÇ ÃֽŠµ¿Çâ
Recent Update of Clinical Drug Trials in Alzheimer¡¯s Disease
´ëÇѽŰæ°úÇÐȸÁö 2015³â 33±Ç 4È£ p.252 ~ p.258
°Èñ¿µ(Kang Hee-Young) - °æ»ó´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ½Å°æ°úÇб³½Ç
¹Ú°æ¿ø(Park Kyung-Won) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç
Abstract
The prevalence of Alzheimer¡¯s disease (AD) is increasing as the global population ages. Currently available treatments for AD target cholinergic and glutamatergic neurotransmission. There have been modest symptomatic effects, but disease modifying effects have not been accomplished. This is even true of clinical trials of bapineuzumab and solanezumab, two humanized monoclonal antibodies that bind amyloid. Therefore, innovations in clinical trial designs are necessary, including revised diagnostic criteria and treatment at the earliest stages of AD. Several prevention trials started in 2013, emphasizing these innovative principles of clinical trial design. In this review, we will discuss the paradigm shift for AD clinical treatment trials and ongoing preventative trials.
Å°¿öµå
Alzheimer¡¯s disease, Disease-modifying treatment, Clinical trial
KMID :
0359720150330040252
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
³úô¼ö¾×»ý¹°Ç¥ ÁöÀÚ(A¥â42, Ÿ¿ì) ȤÀº ¾Æ¹Ð·ÎÀ̵åPET ¿µ»óÀ» ÀÌ¿ëÇÑ Á¶±â ¹ß°ß ¹× Áúº´ÁøÇà ¿¹Ãø µîÀÌ ¾î´À Á¤µµ °¡´ÉÇØÁ³À¸¸ç ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ ÁøÇàÀ» ¾ïÁ¦ÇÏ´Â ´ë±Ô¸ð ÀÓ»ó¾à¹°½ÃÇèÀÌ ´Ù¾çÇÏ°Ô ÁøÇàµÇ°í ÀÖÀ½